Back to top
more

Agenus (AGEN)

(Delayed Data from NSDQ)

$11.69 USD

11.69
3,365,285

+3.39 (40.84%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $11.84 +0.15 (1.28%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Agenus (AGEN) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Agenus (AGEN) delivered earnings and revenue surprises of 50.00% and 38.15%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Allogene (ALLO) Misses on Q3 Earnings, Addresses Clinical Hold

by Zacks Equity Research

Allogene (ALLO) misses earnings estimates for the third quarter. However, the stock rises in after-market trading.

Global Blood's (GBT) Earnings & Revenues Lag Estimates in Q3

by Zacks Equity Research

Global Blood (GBT) reports wider-than-expected loss in the third quarter of 2021 while its revenues miss estimates.

Horizon's (HZNP) Q3 Earnings Beat Estimates, 2021 Guidance Up

by Zacks Equity Research

Horizon's (HZNP) earnings and revenues beat estimates in the third quarter of 2021. The company lifts net sales guidance for 2021.

Ultragenyx's (RARE) Q3 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Ultragenyx (RARE) reports narrower-than-expected loss in the third quarter of 2021 while revenues surpass estimates.

Agenus (AGEN) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Down 33.3% in 4 Weeks, Here's Why Agenus (AGEN) Looks Ripe for a Turnaround

by Zacks Equity Research

The heavy selling pressure might have exhausted for Agenus (AGEN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Agenus (AGEN) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Agenus (AGEN) delivered earnings and revenue surprises of -54.17% and -36.75%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Agenus (AGEN) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bristol-Myers' (BMY) Q2 Earnings Beat, Opdivo Sales Grow

by Zacks Equity Research

Bristol-Myers (BMY) beats on earnings and sales in the second quarter as Opdivo sales revive.

What Makes Agenus (AGEN) a Good Fit for "Trend Investing"

by Zacks Equity Research

Agenus (AGEN) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Vertex (VRTX) Initiates Phase II Study on Pain Candidate

by Zacks Equity Research

Vertex (VRTX) starts phase II study for VX-548 to treat acute pain after bunionectomy surgery & expects to start another phase II study to treat acute pain after abdominoplasty surgery in a few weeks.

Moving Average Crossover Alert: Agenus (AGEN)

by Zacks Equity Research

Agenus (AGEN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Agenus (AGEN) Is a Great Choice for "Trend" Investors, Here's Why

by Zacks Equity Research

Agenus (AGEN) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Biotech Stock Roundup: AGEN, SRPT Surge & BIIB, REGN Provide Pipeline Updates

by Zacks Equity Research

The biotech sector was in focus last week with pipeline and regulatory updates from Agenus (AGEN) and Sarepta (SRPT), among others.

Bristol-Myers (BMY) Teams Up With Agenus for Antibody Program

by Zacks Equity Research

Bristol-Myers (BMY) obtains exclusive license for Agenus' antibody program, AGEN1777, for an upfront payment of $200 million and up to $1.36 billion in milestone payments.

Company News for May 19, 2021

by Zacks Equity Research

Companies In The News Are: WMT, TWLO, WFC, BRK.B, BMY, AGEN

Agenus (AGEN) Soars on Global License Deal With Bristol-Myers

by Zacks Equity Research

Agenus (AGEN) inks a definitive agreement with Bristol-Myers, wherein it will grant license to its bispecific antibody program AGEN1777 and another undisclosed target, to the latter.

Agenus (AGEN) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Agenus (AGEN) delivered earnings and revenue surprises of 12.90% and -46.27%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Agenus (AGEN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Agenus (AGEN) delivered earnings and revenue surprises of 9.09% and 92.69%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Agenus (AGEN) Q4 Earnings Expected to Decline

by Zacks Equity Research

Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Agenus (AGEN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Agenus (AGEN) delivered earnings and revenue surprises of -7.69% and 5.95%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Will Agenus (AGEN) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Agenus (AGEN) Initiates Rolling BLA Submission of Balstilimab

by Zacks Equity Research

Agenus (AGEN) initiates the rolling submission of its BLA to the FDA for balstilimab alone for the treatment of recurrent/metastatic cervical cancer.

Agenus (AGEN) in Focus: Stock Moves 7.6% Higher

by Zacks Equity Research

Agenus (AGEN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.